Biogen Inc header image

Biogen Inc

BIIB

Equity

ISIN US09062X1037 / Valor 1720684

NASDAQ (2024-11-21)
USD 158.01+1.29%

Biogen Inc
UMushroom community rating:

star star star star star
4.40 5 votes No rating yet
NegativeNeutralPositive

About company

Biogen Inc is a prominent biotechnology company that focuses on developing therapies for a range of complex and debilitating diseases. Established in 1978, the company has made significant advancements in the field, particularly in neurology, neuropsychiatry, specialized immunology, and rare diseases. Biogen is known for its innovative treatments for conditions such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's disease. The company is dedicated to serving humanity through scientific research and is committed to creating a healthier, more sustainable, and equitable world.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-31.2%1Y
-38.6%3Y
-45.2%5Y

Performance

25.9%1Y
33.7%3Y
44.0%5Y

Volatility

Market cap

22732 M

Market cap (USD)

Daily traded volume (Shares)

517,092

Daily traded volume (Shares)

1 day high/low

159 / 154.75

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.40

5 votes
Performance:
starstarstarstarstar
4.20
Innovation:
starstarstarstarstar
4.80
Society:
starstarstarstarstar
4.20
Nature:
starstarstarstarstar
4.00
Tonia Zimmermann
Switzerland, 13 Jun 2023
star star star star star
Not just leading in supporting Alzheimer patience, but also pioneering in digital health.
Igor Jovicic
Switzerland, 13 Jun 2023
star star star star star
A company that seems to be making an impact in the biotech sector!
Luba Schoenig
Switzerland, 13 Jun 2023
star star star star star
FDA Advisory Committee recommended the Food and Drug Administration to approve Leqembi, an Alzheimer's drug from Biogen and its Japanese partner Eisai.

EQUITIES OF THE SAME SECTOR

Mochida Seiyaku KK
Mochida Seiyaku KK Mochida Seiyaku KK Valor: 762797
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.84%JPY 3,320.00
Interparfums Inc
Interparfums Inc Interparfums Inc Valor: 833467
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.78%USD 130.66
Unitedhealth Group Inc
Unitedhealth Group Inc Unitedhealth Group Inc Valor: 1078451
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.50%USD 597.49
CVS Health Corp
CVS Health Corp CVS Health Corp Valor: 548525
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.48%USD 57.10
HCA Healthcare Inc
HCA Healthcare Inc HCA Healthcare Inc Valor: 11321027
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.23%USD 332.24
Stryker Corp
Stryker Corp Stryker Corp Valor: 974330
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.16%USD 390.14
IQVIA Holdings Inc
IQVIA Holdings Inc IQVIA Holdings Inc Valor: 39103858
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.66%USD 197.60
Smith & Nephew PLC
Smith & Nephew PLC Smith & Nephew PLC Valor: 1111046
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.69%USD 25.04
Bio-Rad Laboratories Inc
Bio-Rad Laboratories Inc Bio-Rad Laboratories Inc Valor: 912793
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.58%USD 325.58
Teva Pharmaceutical Industries Ltd
Teva Pharmaceutical Industries Ltd Teva Pharmaceutical Industries Ltd Valor: 758744
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.29%USD 17.08